- The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
-
Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, Lee SH, Kim HS, Kim BS
- KMID: 1737597
- Clin Mol Hepatol.
- 2014 Mar;20(1):38-46.
- doi: 10.3350/cmh.2014.20.1.38
BACKGROUND/AIMS: Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was... -
- CITED
-
- Close
- SHARE
-
- Close
- A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
-
You BC, Kim YS, Kim HI, Kim SH, Park SS, Seo YR, Kim SG, Lee SW, Kim HS, Jeong SW, Jang JY, Kim BS
- KMID: 1392906
- Clin Mol Hepatol.
- 2012 Sep;18(3):272-278.
- doi: 10.3350/cmh.2012.18.3.272
BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN alpha-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose... -
- CITED
-
- Close
- SHARE
-
- Close
